Literature DB >> 13679245

Standardization and statistical approaches to therapeutic trials in the R6/2 mouse.

Emma Hockly1, Benjamin Woodman, Amarbirpal Mahal, Cathryn M Lewis, Gillian Bates.   

Abstract

The R6/2 mouse is the most widely used animal model of Huntington's disease (HD), a genetic disorder causing movement disorders, personality changes, dementia, and premature death, for which there is currently no effective therapy. Use of animal models to assess novel therapeutic approaches to HD is currently a major focus of research. Progress in this field will depend upon careful standardization of experimental protocols, and a sophisticated statistical approach. Here we investigate the sources of phenotypic variability in R6/2, and make recommendations for the future use of such models in therapeutic trials.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 13679245     DOI: 10.1016/s0361-9230(03)00185-0

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  62 in total

Review 1.  Translating therapies for Huntington's disease from genetic animal models to clinical trials.

Authors:  Steven M Hersch; Robert J Ferrante
Journal:  NeuroRx       Date:  2004-07

2.  Adenoviral astrocyte-specific expression of BDNF in the striata of mice transgenic for Huntington's disease delays the onset of the motor phenotype.

Authors:  Leticia Arregui; Jorge A Benítez; Luis F Razgado; Paula Vergara; Jose Segovia
Journal:  Cell Mol Neurobiol       Date:  2011-06-17       Impact factor: 5.046

3.  Developmental alterations in Huntington's disease neural cells and pharmacological rescue in cells and mice.

Authors: 
Journal:  Nat Neurosci       Date:  2017-03-20       Impact factor: 24.884

4.  Loss of Hsp70 exacerbates pathogenesis but not levels of fibrillar aggregates in a mouse model of Huntington's disease.

Authors:  Jennifer L Wacker; Shao-Yi Huang; Andrew D Steele; Rebecca Aron; Gregor P Lotz; QuangVu Nguyen; Flaviano Giorgini; Erik D Roberson; Susan Lindquist; Eliezer Masliah; Paul J Muchowski
Journal:  J Neurosci       Date:  2009-07-15       Impact factor: 6.167

5.  Force-plate quantification of progressive behavioral deficits in the R6/2 mouse model of Huntington's disease.

Authors:  Stephen C Fowler; Benjamin R Miller; Thomas W Gaither; Michael A Johnson; George V Rebec
Journal:  Behav Brain Res       Date:  2009-03-28       Impact factor: 3.332

6.  The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.

Authors:  Elizabeth A Thomas; Giovanni Coppola; Paula A Desplats; Bin Tang; Elisabetta Soragni; Ryan Burnett; Fuying Gao; Kelsey M Fitzgerald; Jenna F Borok; David Herman; Daniel H Geschwind; Joel M Gottesfeld
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-30       Impact factor: 11.205

7.  DNA instability in postmitotic neurons.

Authors:  Roman Gonitel; Hilary Moffitt; Kirupa Sathasivam; Ben Woodman; Peter J Detloff; Richard L M Faull; Gillian P Bates
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-25       Impact factor: 11.205

8.  Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease.

Authors:  Hilary Moffitt; Graham D McPhail; Ben Woodman; Carl Hobbs; Gillian P Bates
Journal:  PLoS One       Date:  2009-11-30       Impact factor: 3.240

9.  Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease.

Authors:  Kirupa Sathasivam; Amin Lane; Justin Legleiter; Alice Warley; Ben Woodman; Steve Finkbeiner; Paolo Paganetti; Paul J Muchowski; Stuart Wilson; Gillian P Bates
Journal:  Hum Mol Genet       Date:  2010-01-01       Impact factor: 6.150

10.  The problem of pseudoreplication in neuroscientific studies: is it affecting your analysis?

Authors:  Stanley E Lazic
Journal:  BMC Neurosci       Date:  2010-01-14       Impact factor: 3.288

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.